NCT00355238

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 137 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.

Conditions

• Hepatocellular Carcinoma (HCC)

Interventions

Type	Name	Description
DRUG	brivanib (active)	Tablet, Oral, Brivanib 800 mg, once daily, until progression

Timeline

• Start date: 2006-12-31
• Primary completion: 2010-04-30
• Completion: 2010-04-30
• First posted: 2006-07-21
• Last updated: 2023-12-01
• Results posted: 2023-12-01

Locations

37 sites across 8 countries: United States, France, Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan